Development of shellfish allergy after exposure to dual immune checkpoint blockade.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2018-02-09 eCollection Date: 2018-01-01 DOI:10.2217/hep-2017-0021

Zachary J Brown, Bernd Heinrich, Tim F Greten

引用次数: 3

Abstract

Hepatocellular carcinoma (HCC) is a major health problem worldwide with limited systemic therapies available. Immunotherapy is a fast-moving field that is quickly evolving as a treatment for HCC with three recent clinical trials published treating HCC with immune checkpoint inhibitors with promising results. Checkpoint inhibition may lead to a unique adverse event profile with the potential to cause immune-related adverse events by unbalancing the immune system. Here, we report a case of a 61-year-old male with advanced HCC who developed a shellfish allergy after completing three cycles of combination of tremelimumab and durvalumab therapy.

查看原文本刊更多论文

暴露于双重免疫检查点阻断后贝类过敏的发展。

肝细胞癌(HCC)是世界范围内的一个主要健康问题，可用的全身治疗方法有限。免疫治疗是一个快速发展的领域，作为HCC的治疗方法正在迅速发展，最近发表了三个用免疫检查点抑制剂治疗HCC的临床试验，结果很有希望。检查点抑制可能导致独特的不良事件概况，有可能引起免疫系统失衡的免疫相关不良事件。在这里，我们报告了一例61岁晚期HCC男性患者，在完成tremelimumab和durvalumab联合治疗三个周期后发生贝类过敏。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.